Trial exclusion patterns Phase 2 and Phase 3 retatrutide trials commonly excluded participants with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe gastroparesis, recent major cardiovascular events, severe kidney impairment, type 1 diabetes (in the obesity studies), and pregnancy or breastfeeding
GLP-1 medications were originally developed to help manage type 2 diabetes, but lately, theyve become one of the most polarizing topics in health culture
CJC-1295 No DAC has been researched for its ability to influence GH pulses with extended activity, mimicking natural release patterns
Number two, I assess skin quality, because rapid weight loss and gradual weight loss leave the skin in very different places
Ludolph, A